drugset
drugset / Trial / NCT05406115

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

NCT05406115 ↗

Phase 1 Completed 65 enrolled Amgen
RandomizedSequentialDouble-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.

Timeline

Start
2022-07-26
Primary completion
2023-08-21
Completion
2023-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 786 Unknown — Oral

Indications

obesity disorder